top of page

Executive

Team

LTech_logomark_white(150ppi).png

Learn more about the Lumitron team

MAURIE STANG
EXECUTIVE CHAIRMAN

Mr. Stang is the founder of Lumitron Technology and its executive Chairman. Mr. Stang is also the founder of a number of other successful companies internationally, in the healthcare and technology sectors. These companies span, biotechnology, medical devices and a number of innovations in the “clean-tech” sector. He is currently the Chairman of Nanosonics Limited (ASX:NAN) and Aeris Environmental Limited (ASX:AEI), which are both listed on the Australian Securities Exchange. In addition, he is a founder and director of Henry Schein Halas, a joint venture with the NASDAQ-listed Henry Schein, Inc.

Mr. Stang has also established a number of prominent private companies covering research and development, large scale healthcare distribution and several other highly innovative businesses. These companies have gained market leadership in their respective fields and many have won significant innovation and export awards together with strategic partnerships and licensing agreements with some of the worlds leading companies including GE, 3M, Johnson and Johnson, Getinge and Ecolabs.

Mr. Stang’s business activities and experience span the commercialization of intellectual property across global markets. He has a track record of launching and commercializing a broad range of medical and dental devices. Mr. Stang is also a Principal of Gryphon Capital Pty Limited, an independent investment house that facilitates the financing and development of emerging health-care related entities.

CHRIS BARTY, PH.D.
EXECUTIVE DIRECTOR / CTO

Dr. C.P.J. (Chris) Barty is a co-founder of Lumitron Technologies and its chief technology officer.  Chris' academic background includes Ph.D. and M.S. degrees in applied physics from Stanford University and B.S. degrees, each with honors, in chemistry, physics, and chemical engineering from North Carolina State University. For his many contributions to ultrafast and intense laser technology and to x-ray and gamma-ray source development and applications, Chris has been elected a fellow of several prestigious professional societies including: the American Association for the Advancement of Science (AAAS), the American Physical Society (APS), the Optical Society of America (OSA), the Society for Photo-Optical Instrumentation Engineers (SPIE) and the Institute of Electrical and Electronics Engineers (IEEE).

In 2016 Chris was selected as the recipient of the Harold E. Edgerton Award of the SPIE for his work on ultrafast lasers and laser-based x-ray and gamma-ray science and in 2018 he was selected as the recipient of the R. W. Wood Prize of the Optical Society of America for his pioneering contributions to laser technology and applications.  He is currently the Chairman of the International Committee on Ultrahigh Intensity Lasers (www.ICUIL.org) and is a Distinguished Professor of Physics and Astronomy, Surgery and the Beckman Laser Institute and Medical Clinic at the University of California, Irvine. He has published more than 200 manuscripts, given more than 200 invited lectures and holds 20 patents spanning topics in lasers, optics, materials science, nuclear science, medicine, chemistry, engineering, and physics.

Prior to establishing Lumitron’s operations in Irvine, CA in 2017, Chris spent 17 years at the Lawrence Livermore National Laboratory (LLNL) where he invented the core technologies upon which Lumitron’s x-ray systems are based. At LLNL, he also initiated and/or managed of more than $270M of advanced, laser-related R&D activities, created the $50M/annum Photon Science and Applications Program and was the CTO of the $500M/annum National Ignition Facility and Photon Science Directorate which maintains the world’s largest laser - the $3.2B National Ignition Facility. 

DR. PAUL ROSSO, PH.D.
EXECUTIVE DIRECTOR

Dr. Paul Rosso is an Executive Director of the Company.  Dr. Rosso is a retired executive of 3M Company, with 20 years leadership experience in health care businesses and 14 years leading international companies. Paul’s responsibilities included Vice President 3M Europe, Middle East and Africa, President Sumitomo 3M (Japan), Vice President 3M Southeast Asia, President 3M Korea, and Vice President 3M Medical-Surgical Division.

Dr. Rosso has successfully led multiple entrepreneurial ventures and major new product launches in the healthcare arena. These include the world’s first computer controlled heart-lung machine and microelectronic, multi-programmable hearing devices. Paul holds a Ph.D. in organic photochemistry from the Ohio State University.

DR. RONALD SHNIER
NON-EXECUTIVE DIRECTOR

Dr. Ronald Shnier is a Non-Executive Director of the Company. He completed a radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles (UCLA) in 1991.

 

Dr. Shnier was a consultant specialist at RPAH between 1990 and 1993. He started one of Australia’s first private MRI practices in 1991 before becoming General Manager of Mayne’s Diagnostic Imaging in 2007 and was its National Director for many years. Dr. Shnier has served on several international MRI advisory boards. He has a strong involvement in clinical research, and has lectured both in Australia and overseas.

STEVE SARGENT
NON-EXECUTIVE DIRECTOR

Steve is a Non-Executive Director of Lumitron Technologies.  He is also a non Executive Director of Origin Energy Ltd (ASX:ORG), Nanosonics Ltd (ASX:NAN), The Great Barrier Reef Foundation and is Chairman of OFX Group Ltd (ASX:OFX) and Chairman of the Origin Foundation. Steve has extensive executive experience over the last 36 years having worked with General Electric in a range of industries spanning healthcare, energy, mining and financial services, and having lead businesses across the US, Europe, Asia Pacific and Australia & NZ.  

Steve joined GE Capital in New York City in 1993 and was appointed Vice President and Officer of General Electric Company in 2008. Steve was also a member of GE’s Global Corporate Executive Council and was the first Australian to have been appointed to these roles. Steve’s most recent executive role was President and CEO of GE Mining, GE’s global mining technology and services business.

Previously Steve was a Non Executive Director of Veda Group Ltd (ASX:VED), Bond University Ltd, and was on the board of the Business Council of Australia.

Steve holds a Bachelor of Business from Charles Sturt University and is a Fellow of the Institute of Company Directors and a Fellow with the Australian Academy of Technological Sciences and Engineering.”

LTech_logomark_primary_RGB(300ppi).png
ROBERT J. PHILLIPPY
NON-EXECUTIVE DIRECTOR
FINIAN TAN
NON-EXECUTIVE DIRECTOR
JENNY HARRY
NON-EXECUTIVE DIRECTOR

Mr. Phillippy is a Non-Executive Director for Lumitron Technologies. Mr. Phillippy is the former President and Chief Executive Officer of Newport Corporation, an industry leading Laser, Optics, and Photonics technology company with thousands of products, 15 manufacturing locations in 7 countries, and more than 2500 team members worldwide. This wealth of experience will be vital to nurturing Lumitron’s growth trajectory.

Mr. Phillippy’s impressive resume includes his leadership
tenure at Newport Corporation and member of the Board
of Directors at MKS Instruments, ESCO Technologies,
Kimball Electronics, and Materion Corporation. Prior
to joining Newport, Mr. Phillippy was Vice President of
Channel Marketing at Square D Company. He holds a
Bachelor of Science degree in Electrical Engineering from
the University of Texas and a Master of Management
degree from Northwestern University’s Kellogg Graduate
School of Management.

Dr. Finian Tan is a venture capitalist, entrepreneur, and the Founder and Chairman of Vickers Venture Partners, a top global VC firm established in 2005. Before founding Vickers, Finian was the Founding Partner and Managing Director of Silicon Valley VC firm Draper Fisher Jurvetson ePlanet in Asia, where he led the legendary investment into tech giant Baidu. Some of his other notable

investments include Focus Media, Cambridge Industrial Trust, Asia Food Channel, TWG Tea, M-DAQ, Spark Systems, Matchmove, RWDC industries and Samumed.

 

Prior to DFJ, Dr. Tan was Deputy Secretary of Trade and Industry for the Singapore Government where he oversaw the creation of the billion dollar TIF fund. He received his Doctor of Philosophy and Master of Philosophy in Engineering from Cambridge University. He received his B.Sc. in Engineering from the University of Glasgow.

Dr. Harry is a Non-Executive Director of Lumitron Technologies, Inc.  She is also a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX:NEU), Aeris Environmental Ltd (ASX:AEI) and Genetic Signatures Limited (ASX:GSS). Since joining the Board of Neuren Pharmaceuticals as a NED in 2018 the company has commercialized its first drug with a US partner and successfully completed three Phase 2 trials with its second drug product. Neuren has grown from a market cap of ~$170m to a value of >$2B today and in 2023 the Company was elevated to the ASX200 index.

 

Jenny has had 25 years’ experience in executive roles and as an independent Director on the Boards of private and listed entities - primarily in the biotechnology, pharmaceutical and diagnostic sectors. As a senior executive and CEO she has commercialised a suite of disruptive technologies including reagents, instrumentation and software, negotiated agreements with multinational Companies, raised capital, participated in M&A transactions, and assisted in the establishment and growth of businesses in Australia, the USA and Japan.

Jenny holds a PhD in developmental biology, and is a graduate of the Harvard Business School’s General Management Program and the Australian Institute of Company Directors.

bottom of page